Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Time Posted：2022-03-31 17:48
LIZHU V-01, as the world's first COVID-19 vaccine to achieve protective efficacy against prevalent strains including Omicron, boasts an absolute protective efficacy of 61.35%, rising to 71.83% for individuals with underlying health conditions. This meets WHO effectiveness standards and is comparable to mRNA booster protection. A two-dose inactivated vaccine regimen followed by a V-01 booster may become the optimal combination for safe and effective protection against Omicron and other variants.
Time Posted：2022-03-28 13:35
Lizhu V-01 shows good protective effects in high-risk populations: In a sequential booster phase III clinical trial, a group study of high-risk populations showed that V-01 had a 71.83% protective efficacy in high-risk populations with underlying diseases.
Time Posted：2022-03-25 18:03
HealthGen Group's successful transformation from a health product company to a pharmaceutical company is noteworthy. With two listed companies under its umbrella, HealthGen and Lizhu Pharmaceutical, focusing on innovative drugs and high-barrier complex preparations, it has already created two single products exceeding 1 billion yuan in sales. The group's four new inhaled preparations are expected to begin production this year, striving towards a leading position; seven microsphere preparations are under research, with Curpuli microspheres aiming to be the first domestically produced; it has secured the first domestically produced recombinant HCG, with more than 10 biological drugs in development.
Time Posted：2022-03-25 14:44
In other words, in live virus neutralization tests, the neutralization levels of the Lizhu prototype vaccine and bivalent vaccine were 4.9 and 11.2 times that of the inactivated vaccine, respectively. After boosting with the bivalent vaccine, the neutralization level against Omicron (GMT=77) was equivalent to the neutralization level of three doses of inactivated vaccine against the original strain (GMT=84). The reason why the bivalent vaccine can provide stronger protection may be that the bivalent vaccine has greater antigenic epitope differences, inducing stronger and broader neutralization antibody levels. This is laboratory-level data. In Phase III clinical trials in Pakistan and Malaysia, boosting with Lizhu vaccine (V-01) based on two doses of inactivated vaccine achieved 61.35% absolute protection against Omicron.
Racing Against the Pandemic: China Makes a Breakthrough in Vaccine Development for High-Risk Groups
Time Posted：2022-03-25 14:35
In terms of immune effects, Phase II clinical data of the V-01 vaccine shows that the antibody titer is 3 times higher than that of convalescent serum, which is among the top international level and has the same immune effect on the elderly population. Medical data shows that more effective protection for the elderly is a major highlight of the V-01 vaccine. The elderly have always been a high-risk group for COVID-19 infection, and there are still about 50 million elderly people in China who have not been vaccinated against COVID-19. The good protection of the V-01 vaccine for the elderly population can indeed help improve the overall vaccination rate.
Lizhu antiviral granules can be used to treat mild and ordinary infections of COVID-19.
Time Posted：2022-03-16 15:36
On March 5, 2022, the "Expert Consensus on the Prevention and Treatment of Novel Coronavirus Pneumonia with Traditional Chinese Medicine" was officially published online in the *Chinese Journal of Integrated Traditional and Western Medicine*, including antiviral granules. This expert consensus clarifies the possible mechanisms and optimal intervention time for the prevention and treatment of the epidemic with traditional Chinese medicine. Using the expert consensus method, it comprehensively explains the advantages and value of traditional Chinese medicine in the prevention and treatment of COVID-19, guiding clinicians in the safe and rational use of traditional Chinese medicine. It is expected to provide guidance for the treatment of patients in foreign countries or regions with traditional Chinese medicine and the clinical use of drugs in the future under the normal epidemic prevention and control in China.
Healthy Yuan (600380.SH): Clarithromycin tablets pass the consistency evaluation of generic drugs
Time Posted：2022-03-15 14:49
Zhitong Finance APP reported that Jiankangyuan (600380.SH) announced that recently, its holding subsidiary, Lizhu Pharmaceutical Group Co., Ltd. (“Lizhu Group”), wholly-owned subsidiary Lizhu Pharmaceutical Factory (“Lizhu Pharmaceutical Factory”) received the "Drug Supplement Application Approval Document" issued by the National Medical Products Administration. The clarithromycin tablets produced by Lizhu Pharmaceutical Factory have passed the consistency evaluation of quality and efficacy of generic drugs.
Time Posted：2022-03-11 16:59
Currently, with Omicron raging globally, and standard two-dose vaccination failing to provide sufficient protection against it, adjusting vaccination strategies for more effective Omicron prevention has become a global concern.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.